Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

Post Your Comments:
(Date:11/23/2009)...23/PRNewswire-FirstCall/--CeptionTherapeutics,Inc....n,Inc.(Nasdaq: CEPH )todayannouncedresultsfromaPha...atreatmentforpediatriceosinophilicesophagitis(EoE)...rimaryendpointsofchangesinesophagealeosinophilleve...atpatientstreatedwithCINQUILshowedastatisticallysi...
(Date:11/23/2009)...re/--AdvancedSterilizationProducts(ASP),aleadinggl...odaytheacquisitionbyitsFrenchaffiliate,ApsisS.A.S....vedisinfectionprocessesandtechnologiestopreventhea...renotdisclosed. ,, GlosterEuropedesignsandmarke...videsdisinfectionofpatientenvironmentssuchashospit...
(Date:11/20/2009)...wire/ -- The United States Court of Appeals for t...ruling yesterday, approving a settlement in the lo...tical litigation against AstraZeneca Pharmaceutica...i-bin/prnh/20080317/AQM144LOGO ) ,, The ruling ...rchased the pharmaceutical giant,s prostate cancer...
Breaking Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 1Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 2Cooper University Hospital Reduces Costs and Enhances Patient Care with IP Telephony and Wireless Site Survey 54055 3First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 1First Ever Downloadable Safety in the Home Guides Available Now From VisionAWARE org 54051 2McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 1McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 2McKesson Expands Pharmacy Automation Product Portfolio to Include I V Therapy 13473 3
... SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a bi...commercialization of anti-adhesion, drug delivery ...day that REPEL-CV(R), the company,s,bioresorbable ...ns,following cardiac surgery, has received Health ...undergo open heart surgery. REPEL-CV will be,marke...
..., July 14 MAP,Pharmaceuticals, Inc. (Nasdaq: MAP...linical program to evaluate MAP0004 as a potential...ed and self-administered at home using MAP,Pharmac...pany,s prior Phase,2 efficacy study, MAP0004 provi...ef sustained through at least 24 hours. The study ...
Other Medicine Technology:SyntheMed Receives Canadian Approval for REPEL-CV(R) 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4
(Date:11/23/2009)...-FirstCall/-- ,, DearIsisSupportersandSharehold...ntinuingsupportofIsis.Webelieveweareatoneofthemost...thebeginningofcreatingauniquecompanywithanoveldrug...issueshauntingthepharmaceuticalindustry. ,, Our...shipdrug,mipomersen.Mipomersencontinuestoperformwe...
(Date:11/23/2009)...ylCompanies,thenation,sleadingproviderofoutsourced...edrecognitionasoneofthetopoutsourcingfirmsinhealth...magazine.Berylwasrankedamongthepublication,stop20o...hichenabledittoclimbfromtwelfthplacein2007totenthp...veproducts,suchasitsnewestlaunchofpost-dischargese...
(Date:11/23/2009)...rstCall/--ArcadiaResources,Inc.(NYSEAmex: KAD ),al...esundertheArcadiaHealthCare(SM)()brand,announcedto...haresofitscommonstockandwarrantstopurchasecommonst...nalinvestors,representinggrossproceedstoArcadiaofa...arateSubscriptionAgreementswiththeinvestors,Arcadi...
(Date:11/23/2009)...ascular Services, a division of Baptist Medical Ce...ddition of Aquapheresis Therapy using the Aquadex ...t of patients with fluid overload – helping ... Jackson, Miss. (Vocus) November 2...om fluid overload, time is of the essence. Excess ...
(Date:11/23/2009)...al,sDirectNutritionals,LLC,worldwidedistributorofD...siteCookieDiet.com( www.CookieDiet.com ),todayanno...pularhunger-satisfyingcookiesareavailableonSamsclu...,Sam,sClub. ,, "We,reproudtowelcomeSamsclub.com...l,sCookieDietproducts,andtheonlymembershipdiscount...
Breaking Medicine News(10 mins):Health News:The Beryl Companies Named One of the 'Top 10 Outsourcing Firms' in Healthcare 2Health News:Arcadia Resources Announces Closing of $11.1 Million Financing 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 2Health News:Baptist Cardiovascular Services Introduces New Technology for Congestive Heart Failure Treatment 3Health News:Dr. Siegal's COOKIE DIET(R) Cookies Available at Samsclub.com 2
...rom Australia have made the biggest breakthrough i...of common genes linked to the disease//. Res... Research, working with an international team, con...eveloping breast cancer Dr. Georgia Chenevix-Tr...
... by Cancer Research UK says that obese people are ...nd think they must slim down// only to look good. ...nd that 40% thought looking good was the main reas...ve when it comes to looking after our bodies and t...
...The United States Department of Agriculture (USDA)...al Supplemental Nutrition Program// for Women, Inf...DA's proposal will look at reducing the quantity o...a half dozen eggs to one dozen for children, pregn...
...o Haemorrhagic Fever (CCHF) has killed at least 20...ver reported since it was identified// in 1944, sa...ases of the Ebola-like disease are bound to be re...e, Amasya, Yozagat and Corum have been affected by...
...ing system combining digital photography with Inte...hod to screen for a common childhood oral disease/...toddlers. Early childhood dental caries (E... that results in extensive tooth decay. The condi...
...thers may someday get a personalized menu of foods...ic makeup as a result of new research at Washingto... Researchers used transparent fish embryos to d...the fetus' organs is essentially complete," said B...
Other Medicine News:Health News:Proposal to revamp WIC food package 2Health News:Crimean-Congo Hemorrhagic Fever hits Turkey 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 2Health News:New Screening System For Early Detection Of Dental Caries in Toddlers 3Health News:Unmasking Nutrition's Role in Genes and Birth Defects 2Health News:Unmasking Nutrition's Role in Genes and Birth Defects 3
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: